Neuromyelitis Optica Spectrum Disorder (NMOSD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 

Neuromyelitis optica spectrum disorder (NMOSD) presents as an autoimmune astrocytopathy targeting the central nervous system, characterized by inflammation primarily affecting the optic nerve and spinal cord, with potential involvement of the brainstem, notably the area postrema. While its etiology remains elusive, recent studies have distinguished NMOSD from multiple sclerosis (MS) in terms of disease mechanisms, clinical features, and therapeutic approaches. Whole-genome sequencing has identified certain genotypes predisposing individuals to NMOSD, notably major histocompatibility complexes such as HLA-DRB1*03:01, which exhibit similarities to systemic lupus erythematosus (SLE) rather than MS. The hallmark of NMOSD is the presence of IgG antibodies against aquaporin-4, detected in most patients, particularly in regions rich in aquaporin-4, such as the optic nerve, spinal cord, and area posttrauma. This autoimmune process mediated by aquaporin-4 antibodies leads to perivascular lymphocytic infiltration and subsequent axonal loss, predominantly affecting susceptible regions. Diagnostic evaluation of NMOSD involves clinical assessment, serologic testing for aquaporin-4 antibodies, and magnetic resonance imaging (MRI) with gadolinium enhancement. International consensus diagnostic criteria categorize NMOSD based on aquaporin-4 antibody status and define clinical and MRI features. Notable findings may include decreased color vision and central scotomas on visual field testing. In the differential diagnosis of optic neuritis, NMOSD should be distinguished from MS and MOG antibody-associated disease (MOGAD). MS is the most common, but NMOSD and MOGAD necessitate careful consideration due to their distinct prognostic implications and treatment requirements. Complications of NMOSD encompass visual field defects, motor impairment, and, in severe cases, myogenic respiratory failure, leading to increased mortality. Advances in understanding NMOSD pathogenesis have led to the development of monoclonal antibodies targeting various components of the immune response, including B-cells, the complement pathway, and interleukin 6 (IL-6), yielding therapeutic options such as ibalizumab, eculizumab, eculizumab, and natalizumab.

  • Despite progress in NMOSD treatment, a treatment gap persists, particularly in the pediatric population, with NMOSD affecting approximately 1-5 individuals per 100,000 worldwide.

Thelansis’s “Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neuromyelitis Optica Spectrum Disorder (NMOSD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Neuromyelitis Optica Spectrum Disorder (NMOSD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Neuromyelitis Optica Spectrum Disorder (NMOSD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more